Literature DB >> 28236849

Should metformin be included in fertility treatment of PCOS patients?

Jigal Haas1, Yaakov Bentov2.   

Abstract

Metformin, a drug developed for the treatment of patients with type II diabetes, has become commonly prescribed medication for PCOS patients. Initially, metformin was prescribed for patients with impaired glucose tolerance at the pre conception period, however more recently its use was expanded to many of the PCOS patients and for the whole duration of pregnancy. Several studies examining the effects of Metformin during pregnancy reported a lower pregnancy loss, reduced gestational diabetes and no increased risk for birth defects, however, several more recent studies also raised concerns about its safe use. The therapeutic effect of metformin stems from its ability to inhibit the action of the first complex of the electron transport resulting in reduced ATP production. At the initial stages of embryo development, the only source of ATP is the mitochondrial electron transport chain. Lowering ATP production at the critical stage of early embryo development may impair oocyte maturation and embryo development as well as reprogram the metabolic characteristics of the offspring.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28236849     DOI: 10.1016/j.mehy.2017.01.012

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Comment: Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes-a 5-year national population-based cohort study.

Authors:  A Lapolla; S Burlina; M G Dalfrà
Journal:  J Endocrinol Invest       Date:  2021-07-06       Impact factor: 4.256

2.  IGF-1R and Leptin Expression Profile and the Effects of Metformin Treatment on Metabolic and Endocrine Parameters in PCOS Mice.

Authors:  Luis Eduardo Prado Correia; Bruna Cristine de Almeida; Manuel de Jesus Simões; Mauro Abi Haidar; Daniela Berguio Vidotti; Ivaldo Silva
Journal:  Biomed Res Int       Date:  2017-12-21       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.